Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

nt for Korean patients (pts) with wild-type epidermal growth factor receptor (wtEGFR) stage IIIB/IV lung adenocarcinoma

Myung-Ju Ahn Ahn,

MD

 

ESMO Abstract # 1292P
Date: Saturday, September 29
Time:  13:00 – 14:00 PM CESTActivity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors

Yelena Y. Janjigian,

MD

ESMO Abstract # 1227O
Date: Sunday, September 30
Time: 9:00 - 11:00 AM CESTLUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

Lecia V. Sequist,

MD, MPH

ESMO Abstract # 1229PD

Date: Sunday, September 30

Time: 12:45 – 14:15pm CESTA Phase I study of daily afatinib, an irreversible ErbB family blocker, combined with weekly paclitaxel and 2-weekly bevacizumab in patients with advanced solid tumours

 

Deborah Enting

 

ESMO Abstract # 464P
Date: Monday, October 1
Time: 13:00 – 14:00 PM CESTPhase I study to compare safety and pharmacokinetics of afatinib, an oral irreversible ErbB family blocker, in non-cancer subjects with hepatic impairment to matched healthy subjects

David Schnell,

MD

ESMO Abstract # 468P
Date: Monday, October 1
Time: 13:00 – 14:00 PM CESTPhase I safety and tolerability of once daily oral afatinib (A) (BIBW 2992) in combination with gemcitabine (G) in patients (pts) with advanced solid tumours

Sylvie Zanetta,

MD

ESMO Abstract # 478P
Date: Monday, October 1
Time: 13:00 – 14:00 PM CESTPhase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumours

Helene Senellart,

MD, PhD

ESMO Abst
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group ... is teaming up with the Heartland Blood Center and offering ... drive. The drive takes place Saturday, Jan. 18 at the ... 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... HARBIN, China, April 23 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... CSKI ), a,leading fully integrated pharmaceutical company ... today announced that it,obtained approvals from the State Food ... Geranium ointment and Musk liniment for pain relief. , ...
... China and LOS ANGELES, April 23 /PRNewswire-Asia-FirstCall/ --, - Fourth ... Income was $0.9 Million and Diluted EPS of $.03, ... - 2008 Gross Profit Margin Improved 340 Basis Points to 20.1%, ... EPS of, $0.13, - 2008 ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the ... and internationally, which recently announced it has decreased long-term ... has eliminated another $817,000 of long-term debt. "The remaining ...
Cached Biology Technology:China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 2China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 5China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 6China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 8China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 9China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 10China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 11Cord Blood America Further Reduction, $817,000, in Long-Term Debt 2
(Date:4/23/2014)... the family of bacteria that causes whooping cough ... surprising findings about the bacteria,s origin and evolution. ... to control this respiratory disease, which kills 195,000 ... 343 strains of the Bordetella pertussis ... last 100 years illustrates how vaccination has shaped ...
(Date:4/23/2014)... new study by a University of Exeter researcher has ... of wild camels thriving in Australia,s remote outback have ... scale. , Sarah Crowley, of the Environment and Sustainability ... the history of the camel in Australia, from their ... to their current status as unwelcome "invader." , The ...
(Date:4/23/2014)... many social mammals, ravens form different types of social ... and they also form strict dominance relations. From a ... a key ability in daily social life ("knowing who ... group members have with each other sets the stage ... results of this study have been published in the ...
Breaking Biology News(10 mins):Impact of whooping cough vaccination revealed 2How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Ravens understand the relations among others 2
... peak in sight fitness peak, that is for ... Lenski, MSU Hannah Distinguished Professor of Microbiology and Molecular Genetics, ... generating more than 50,000 generations. In a paper published in ... author and MSU graduate student in Lenski,s lab, compares it ...
... genetic signature of respiratory syncytial virus (RSV), the leading cause ... key step toward a better understanding of the immune response ... and a tool that could allow physicians to determine the ... from a team at The Research Institute at Nationwide Children,s ...
... may be more able to cope with dry conditions ... and Colorado State University used a computer model to ... the Amazon rainforest may be more able to withstand ... climate models. Many climate models over predict the ...
Cached Biology News:No peak in sight for evolving bacteria 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 3Amazon rainforest more able to withstand drought than previously thought 2
... Coating Stabilizer has been developed ... or immobilized proteins on microwell plates/strips. ... and activity of the antibody or ... immunoassay components. Product is filtered ...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: